This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Corcept Therapeutics Inc.
Drug Names(s): C-1073, RU-486, Corlux, Corluxin (EU)
Description: CORLUX is a potent antagonist of one of the body's two cortisol receptors and its progesterone receptor. The mechanism by which cortisol affects target cells is by binding to a cortisol receptor. Two cortisol receptors have been identified - named GRI and GRII. Once bound, the receptor-cortisol combination turns on a cascade of events in the cell. Elevated cortisol leads to activation of the GR-II receptor. Sustained activation of the GRII receptor can result in psychiatric disturbances. CORLUX potently blocks the GRII receptor without blocking the GRI receptor. (The active ingredient of Corlux, mifepristone, is approved in another drug [Mifeprex, which had been known as RU-486, 200 mg] for terminating pregnancies.)
Deal Structure: Corcept has exclusively licensed three issued U.S. patents from Stanford University for the use of GR-II antagonists in the treatment of psychotic major depression, cocaine-induced psychosis and early dementia, including early Alzheimer's disease. The company bears the costs of protecting and defending the rights to these patents. In order to maintain the exclusive license to these patents until their expiration, Corcept is obligated to make milestone and royalty payments to Stanford University.
Additional information available to subscribers only: